Narasimhan VM, Xue Y, Tyler-Smith C. Human knockout carriers: dead, diseased, healthy, or improved? Trends Mol Med. 2016;22:341–51.

PubMed  PubMed Central  Google Scholar 

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.

CAS  PubMed  Google Scholar 

Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–5.

CAS  PubMed  PubMed Central  Google Scholar 

Rhee EP, Yang Q, Yu B, Liu X, Cheng S, Deik A, et al. An exome array study of the plasma metabolome. Nat Commun. 2016;7:12360.

CAS  PubMed  PubMed Central  Google Scholar 

McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, et al. Common deletion polymorphisms in the human genome. Nat Genet. 2006;38:86–92.

CAS  PubMed  Google Scholar 

Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, et al. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med. 2018;20:622–9.

CAS  PubMed  Google Scholar 

Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83:337–46.

CAS  PubMed  PubMed Central  Google Scholar 

Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2021. Nucleic Acids Res. 2021;49:D884–D891.

CAS  PubMed  Google Scholar 

Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM, et al. The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. Cancer. 2013;119:2477–85.

CAS  PubMed  Google Scholar 

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, et al. The UGT2B28 sex-steroid inactivation pathway is a regulator of steroidogenesis and modifies the risk of prostate cancer progression. Eur Urol. 2016;69:601–9.

CAS  PubMed  Google Scholar 

Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, et al. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? Haematologica. 2016;101:e63–65.

CAS  PubMed  PubMed Central  Google Scholar 

Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood. 2013;121:1175–83.

CAS  PubMed  Google Scholar 

Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab. 2011;96:E1550–1557.

CAS  PubMed  Google Scholar 

Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Stenzel B, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2010;19:229–39.

CAS  Google Scholar 

Albertsen HM, Matalliotaki C, Matalliotakis M, Zervou MI, Matalliotakis I, Spandidos DA, et al. Whole exome sequencing identifies hemizygous deletions in the UGT2B28 and USP17L2 genes in a three generation family with endometriosis. Mol Med Rep. 2019;19:1716–20.

CAS  PubMed  PubMed Central  Google Scholar 

Bronstad I, Wolff AS, Lovas K, Knappskog PM, Husebye ES. Genome-wide copy number variation (CNV) in patients with autoimmune Addison’s disease. BMC Med Genet. 2011;12:111.

PubMed  PubMed Central  Google Scholar 

Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect Prev. 2007;31:310–5.

CAS  PubMed  PubMed Central  Google Scholar 

Giroux S, Bussieres J, Bureau A, Rousseau F. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women. Osteoporos Int. 2012;23:1163–70.

CAS  PubMed  Google Scholar 

Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008;8:147–51.

CAS  PubMed  Google Scholar 

Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, et al. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. Br J Cancer. 2020;122:1068–76.

CAS  PubMed  PubMed Central  Google Scholar 

McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009;41:1341–4.

CAS  PubMed  PubMed Central  Google Scholar 

Shen Q, Lee K, Han SK, Ahn HJ, Kim S, Lee JH. Variants at potential loci associated with Sjogren’s syndrome in Koreans: a genetic association study. Clin Immunol. 2019;207:79–86.

CAS  PubMed  Google Scholar 

Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet. 2008;83:663–74.

CAS  PubMed  PubMed Central  Google Scholar 

Allain EP, Rouleau M, Levesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020;122:1277–87.

PubMed  PubMed Central  Google Scholar 

Levesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Belanger A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001;40:3869–81.

CAS  PubMed  Google Scholar 

Ekstrom L, Cevenini L, Michelini E, Schulze J, Thorngren JO, Belanger A, et al. Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes. Eur J Clin Invest. 2013;43:248–55.

PubMed  Google Scholar 

Juul A, Sorensen K, Aksglaede L, Garn I, Rajpert-De Meyts E, Hullstein I, et al. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. J Clin Endocrinol Metab. 2009;94:1005–11.

CAS  PubMed  Google Scholar 

Schulze JJ, Mullen JE, Berglund Lindgren E, Ericsson M, Ekstrom L, Hirschberg AL. The impact of genetics and hormonal contraceptives on the steroid profile in female athletes. Front Endocrinol. 2014;5:50.

Google Scholar 

Strahm E, Mullen JE, Garevik N, Ericsson M, Schulze JJ, Rane A, et al. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test Anal. 2015;7:1063–70.

CAS  PubMed  Google Scholar 

Mouritsen A, Busch AS, Aksglaede L, Rajpert-De Meyts E, Juul A. Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys. Endocr Connect. 2018;7:460–5.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Dai Y, Tu Z, Li Q, Wang L, Zhang L. Array-CGH detection of UGT2B28 gene deletion in a girl with primary amenorrhea and hyperandrogenism. Int J Gynaecol Obstet. 2010;109:164–6.

CAS  PubMed  Google Scholar 

Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, et al. Integrated metabolomics and proteomics highlight altered nicotinamide- and polyamine pathways in lung adenocarcinoma. Carcinogenesis. 2017;38:271–80.

CAS  PubMed  PubMed Central  Google Scholar 

Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, et al. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014;13:1088–1100.

CAS  PubMed  Google Scholar 

Rosario SR, Long MD, Affronti HC, Rowsam AM, Eng KH, Smiraglia DJ. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat Commun. 2018;9:5330.

CAS  PubMed  PubMed Central  Google Scholar 

Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, et al. A comprehensive analysis of steroid hormones and progression of localized high-risk prostate cancer. Cancer Epidemiol Biomark Prev. 2019;28:701–6.

CAS  Google Scholar 

Menard V, Eap O, Harvey M, Guillemette C, Levesque E. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism. Hum Mutat. 2009;30:1310–9.

CAS  PubMed  Google Scholar 

Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab. 2003;14:473–9.

CAS  PubMed  Google Scholar 

Lofgren L, Stahlman M, Forsberg GB, Saarinen S, Nilsson R, Hansson GI. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res. 2012;53:1690–1700.

PubMed  PubMed Central  Google Scholar 

Caron P, Turcotte V, Guillemette C. A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume. Steroids. 2015;104:16–24.

CAS  PubMed  Google Scholar 

Caron P, Turcotte V, Guillemette C. A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. J Chromatogr A. 2021;1650:462228.

CAS  PubMed  Google Scholar 

Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, Aprikian A, et al. Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. Br J Cancer. 2021;125:78–84.

CAS